StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Equities researchers at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Several other analysts have also recently commented on NSPR. Lake Street Capital began coverage on InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Trading Up 0.8 %

Shares of NSPR opened at $2.67 on Monday. The business’s 50-day moving average price is $2.77 and its 200 day moving average price is $2.71. The stock has a market capitalization of $69.64 million, a P/E ratio of -3.56 and a beta of 0.99. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42.

InspireMD (NYSE:NSPR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million for the quarter, compared to the consensus estimate of $1.74 million. During the same period last year, the firm posted ($0.15) earnings per share. On average, research analysts predict that InspireMD will post -0.79 earnings per share for the current year.

Institutional Trading of InspireMD

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC purchased a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD as of its most recent SEC filing. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.